Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 893 entries
Sorted by: Best Match Show Resources per page
Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy.

Urologic oncology

Nejat RJ, Purohit R, Goluboff ET, Petrylak D, Rubin MA, Benson MC.
PMID: 11166621
Urol Oncol. 2001 Mar;6(2):53-55. doi: 10.1016/s1078-1439(00)00098-3.

Small cell carcinoma (SCC) of the urinary bladder is a rare, aggressive malignancy with approximately 135 cases reported in the literature. Treatments have included chemotherapy, radical surgery, radiotherapy, and combinations of these. We present the apparent cure of a...

Cite
Nejat RJ, Purohit R, Goluboff ET, et al. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urol Oncol. 2001;6(2):53-55doi: 10.1016/s1078-1439(00)00098-3.
Nejat, R. J., Purohit, R., Goluboff, E. T., Petrylak, D., Rubin, M. A., & Benson, M. C. (2001). Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urologic oncology, 6(2), 53-55. https://doi.org/10.1016/s1078-1439(00)00098-3
Nejat, R J., et al. "Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy." Urologic oncology vol. 6,2 (2001): 53-55. doi: https://doi.org/10.1016/s1078-1439(00)00098-3
Nejat RJ, Purohit R, Goluboff ET, Petrylak D, Rubin MA, Benson MC. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urol Oncol. 2001 Mar;6(2):53-55. doi: 10.1016/s1078-1439(00)00098-3. PMID: 11166621.
Copy Download .nbib Format: NLM
p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma.

Urologic oncology

Olumi AF, Weidner N, Presti JC.
PMID: 11166623
Urol Oncol. 2001 Mar;6(2):63-67. doi: 10.1016/s1078-1439(00)00109-5.

This study assessed the relation of proliferation, inhibition of apoptosis, and the p53 tumor suppressor protein expression in clear renal cell carcinoma (RCC). Archival pathological specimens from 43 patients treated for RCC were obtained. Median follow-up for the patients...

Cite
Olumi AF, Weidner N, Presti JC. p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. Urol Oncol. 2001;6(2):63-67doi: 10.1016/s1078-1439(00)00109-5.
Olumi, A. F., Weidner, N., & Presti, J. C. (2001). p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. Urologic oncology, 6(2), 63-67. https://doi.org/10.1016/s1078-1439(00)00109-5
Olumi, A F., et al. "p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma." Urologic oncology vol. 6,2 (2001): 63-67. doi: https://doi.org/10.1016/s1078-1439(00)00109-5
Olumi AF, Weidner N, Presti JC. p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. Urol Oncol. 2001 Mar;6(2):63-67. doi: 10.1016/s1078-1439(00)00109-5. PMID: 11166623.
Copy Download .nbib Format: NLM
Extended sector biopsy for detection of carcinoma of the prostate.

Urologic oncology

M D PM, Niemann TH, Bahnson RR.
PMID: 11343997
Urol Oncol. 2001 May;6(3):91-93. doi: 10.1016/s1078-1439(00)00111-3.

Purpose: To determine whether an extended sector biopsy of the prostate will increase the detection of prostate cancer, without causing an increase in morbidity. Materials and Methods: A total of 74 men with a mean age of 62.3 years...

Cite
M D PM, Niemann TH, Bahnson RR. Extended sector biopsy for detection of carcinoma of the prostate. Urol Oncol. 2001;6(3):91-93doi: 10.1016/s1078-1439(00)00111-3.
M D , P. M., Niemann, T. H., & Bahnson, R. R. (2001). Extended sector biopsy for detection of carcinoma of the prostate. Urologic oncology, 6(3), 91-93. https://doi.org/10.1016/s1078-1439(00)00111-3
M D , P M.A., et al. "Extended sector biopsy for detection of carcinoma of the prostate." Urologic oncology vol. 6,3 (2001): 91-93. doi: https://doi.org/10.1016/s1078-1439(00)00111-3
M D PM, Niemann TH, Bahnson RR. Extended sector biopsy for detection of carcinoma of the prostate. Urol Oncol. 2001 May;6(3):91-93. doi: 10.1016/s1078-1439(00)00111-3. PMID: 11343997.
Copy Download .nbib Format: NLM
Clinical trials of immunotherapy for advanced prostate cancer.

Urologic oncology

Kuratsukuri K, Nishisaka N, Jones RF, Wang CY, Haas GP.
PMID: 11008095
Urol Oncol. 2000 Nov 01;5(6):265-273. doi: 10.1016/s1078-1439(00)00086-7.

There is a lack of effective therapeutic regimens for advanced hormone-refractory prostate cancer (HRPC). Recent combination regimens of chemotherapy have improved management of HRPC. Neither systemic chemotherapy nor radiation regimens have significantly improved survival. Conventional systemic cytokine therapy has...

Cite
Kuratsukuri K, Nishisaka N, Jones RF, et al. Clinical trials of immunotherapy for advanced prostate cancer. Urol Oncol. 2000;5(6):265-273doi: 10.1016/s1078-1439(00)00086-7.
Kuratsukuri, K., Nishisaka, N., Jones, R. F., Wang, C. Y., & Haas, G. P. (2000). Clinical trials of immunotherapy for advanced prostate cancer. Urologic oncology, 5(6), 265-273. https://doi.org/10.1016/s1078-1439(00)00086-7
Kuratsukuri, et al. "Clinical trials of immunotherapy for advanced prostate cancer." Urologic oncology vol. 5,6 (2000): 265-273. doi: https://doi.org/10.1016/s1078-1439(00)00086-7
Kuratsukuri K, Nishisaka N, Jones RF, Wang CY, Haas GP. Clinical trials of immunotherapy for advanced prostate cancer. Urol Oncol. 2000 Nov 01;5(6):265-273. doi: 10.1016/s1078-1439(00)00086-7. PMID: 11008095.
Copy Download .nbib Format: NLM
The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer.

Urologic oncology

Grossman HB.
PMID: 10973706
Urol Oncol. 2000 Sep 01;5(5):183-184. doi: 10.1016/s1078-1439(00)00080-6.

No abstract available.

Cite
Grossman HB. The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer. Urol Oncol. 2000;5(5):183-184doi: 10.1016/s1078-1439(00)00080-6.
Grossman, H. B. (2000). The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer. Urologic oncology, 5(5), 183-184. https://doi.org/10.1016/s1078-1439(00)00080-6
Grossman. "The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer." Urologic oncology vol. 5,5 (2000): 183-184. doi: https://doi.org/10.1016/s1078-1439(00)00080-6
Grossman HB. The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer. Urol Oncol. 2000 Sep 01;5(5):183-184. doi: 10.1016/s1078-1439(00)00080-6. PMID: 10973706.
Copy Download .nbib Format: NLM
Genetic alterations and biological pathways in human bladder cancer pathogenesis.

Urologic oncology

Reznikoff CA, Sarkar S, Jülicher KP, Burger MS, Puthenveettil JA, Jarrard DF, Newton MA.
PMID: 10973707
Urol Oncol. 2000 Sep 01;5(5):191-203. doi: 10.1016/s1078-1439(00)00079-x.

Human bladder cancers are heterogeneous. For example, at first presentation papillary transitional cell carcinomas (TCCs) are typically superficial and often multifocal. Papillary TCCs frequently recur, but most never progress to invasive TCC. In contrast, bladder carcinoma in situ (CIS)...

Cite
Reznikoff CA, Sarkar S, Jülicher KP, et al. Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol. 2000;5(5):191-203doi: 10.1016/s1078-1439(00)00079-x.
Reznikoff, C. A., Sarkar, S., Jülicher, K. P., Burger, M. S., Puthenveettil, J. A., Jarrard, D. F., & Newton, M. A. (2000). Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urologic oncology, 5(5), 191-203. https://doi.org/10.1016/s1078-1439(00)00079-x
Reznikoff, et al. "Genetic alterations and biological pathways in human bladder cancer pathogenesis." Urologic oncology vol. 5,5 (2000): 191-203. doi: https://doi.org/10.1016/s1078-1439(00)00079-x
Reznikoff CA, Sarkar S, Jülicher KP, Burger MS, Puthenveettil JA, Jarrard DF, Newton MA. Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol. 2000 Sep 01;5(5):191-203. doi: 10.1016/s1078-1439(00)00079-x. PMID: 10973707.
Copy Download .nbib Format: NLM
p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?.

Urologic oncology

Schmitz-Dräger BJ, Goebell PJ, Heydthausen M.
PMID: 10973708
Urol Oncol. 2000 Sep 01;5(5):204-210. doi: 10.1016/s1078-1439(00)00078-8.

Seven years after the initial reports of the potential prognostic value of p53 immunohistochemistry in bladder cancer, key questions remain unanswered. This is mainly due to conflicting results obtained through multiple retrospective trials mostly performed with small numbers of...

Cite
Schmitz-Dräger BJ, Goebell PJ, Heydthausen M. p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?. Urol Oncol. 2000;5(5):204-210doi: 10.1016/s1078-1439(00)00078-8.
Schmitz-Dräger, B. J., Goebell, P. J., & Heydthausen, M. (2000). p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?. Urologic oncology, 5(5), 204-210. https://doi.org/10.1016/s1078-1439(00)00078-8
Schmitz-Dräger, et al. "p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?." Urologic oncology vol. 5,5 (2000): 204-210. doi: https://doi.org/10.1016/s1078-1439(00)00078-8
Schmitz-Dräger BJ, Goebell PJ, Heydthausen M. p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?. Urol Oncol. 2000 Sep 01;5(5):204-210. doi: 10.1016/s1078-1439(00)00078-8. PMID: 10973708.
Copy Download .nbib Format: NLM
Development of markers of prostate cancer metastasis. Review and perspective.

Urologic oncology

Christiano AP, Yoshida BA, Dubauskas Z, Sokoloff M, Rinker-Schaeffer CW.
PMID: 10973711
Urol Oncol. 2000 Sep 01;5(5):217-223. doi: 10.1016/s1078-1439(00)00070-3.

No abstract available.

Cite
Christiano AP, Yoshida BA, Dubauskas Z, et al. Development of markers of prostate cancer metastasis. Review and perspective. Urol Oncol. 2000;5(5):217-223doi: 10.1016/s1078-1439(00)00070-3.
Christiano, A. P., Yoshida, B. A., Dubauskas, Z., Sokoloff, M., & Rinker-Schaeffer, C. W. (2000). Development of markers of prostate cancer metastasis. Review and perspective. Urologic oncology, 5(5), 217-223. https://doi.org/10.1016/s1078-1439(00)00070-3
Christiano, et al. "Development of markers of prostate cancer metastasis. Review and perspective." Urologic oncology vol. 5,5 (2000): 217-223. doi: https://doi.org/10.1016/s1078-1439(00)00070-3
Christiano AP, Yoshida BA, Dubauskas Z, Sokoloff M, Rinker-Schaeffer CW. Development of markers of prostate cancer metastasis. Review and perspective. Urol Oncol. 2000 Sep 01;5(5):217-223. doi: 10.1016/s1078-1439(00)00070-3. PMID: 10973711.
Copy Download .nbib Format: NLM
Urinary diversion and bladder substitution in patients with bladder cancer.

Urologic oncology

Davidsson T, Wullt B, Könyves J, Månsson A, Månsson W.
PMID: 10973712
Urol Oncol. 2000 Sep 01;5(5):224-231. doi: 10.1016/s1078-1439(00)00069-7.

For the majority of patients with invasive bladder carcinoma, radical cystectomy remains the gold standard of care. As a result the twentieth century has seen the continuous development of methods for reconstructing the urinary tract. Two decades ago the...

Cite
Davidsson T, Wullt B, Könyves J, et al. Urinary diversion and bladder substitution in patients with bladder cancer. Urol Oncol. 2000;5(5):224-231doi: 10.1016/s1078-1439(00)00069-7.
Davidsson, T., Wullt, B., Könyves, J., Månsson, A., & Månsson, W. (2000). Urinary diversion and bladder substitution in patients with bladder cancer. Urologic oncology, 5(5), 224-231. https://doi.org/10.1016/s1078-1439(00)00069-7
Davidsson, et al. "Urinary diversion and bladder substitution in patients with bladder cancer." Urologic oncology vol. 5,5 (2000): 224-231. doi: https://doi.org/10.1016/s1078-1439(00)00069-7
Davidsson T, Wullt B, Könyves J, Månsson A, Månsson W. Urinary diversion and bladder substitution in patients with bladder cancer. Urol Oncol. 2000 Sep 01;5(5):224-231. doi: 10.1016/s1078-1439(00)00069-7. PMID: 10973712.
Copy Download .nbib Format: NLM
Commentary. urinary diversion and bladder substitution in patients with bladder cancer.

Urologic oncology

Stein JP.
PMID: 10973713
Urol Oncol. 2000 Sep 01;5(5):232-233. doi: 10.1016/s1078-1439(00)00096-x.

No abstract available.

Cite
Stein JP. Commentary. urinary diversion and bladder substitution in patients with bladder cancer. Urol Oncol. 2000;5(5):232-233doi: 10.1016/s1078-1439(00)00096-x.
Stein, J. P. (2000). Commentary. urinary diversion and bladder substitution in patients with bladder cancer. Urologic oncology, 5(5), 232-233. https://doi.org/10.1016/s1078-1439(00)00096-x
Stein. "Commentary. urinary diversion and bladder substitution in patients with bladder cancer." Urologic oncology vol. 5,5 (2000): 232-233. doi: https://doi.org/10.1016/s1078-1439(00)00096-x
Stein JP. Commentary. urinary diversion and bladder substitution in patients with bladder cancer. Urol Oncol. 2000 Sep 01;5(5):232-233. doi: 10.1016/s1078-1439(00)00096-x. PMID: 10973713.
Copy Download .nbib Format: NLM
Timing of cystectomy for superficial bladder tumors.

Urologic oncology

Herr HW.
PMID: 10869959
Urol Oncol. 2000 Jul 01;5(4):162-165. doi: 10.1016/s1078-1439(00)00061-2.

Timing of radical cystectomy in patients undergoing treatment and follow up for superficial bladder tumors is discussed with an algorithm for patient decisions.

Cite
Herr HW. Timing of cystectomy for superficial bladder tumors. Urol Oncol. 2000;5(4):162-165doi: 10.1016/s1078-1439(00)00061-2.
Herr, H. W. (2000). Timing of cystectomy for superficial bladder tumors. Urologic oncology, 5(4), 162-165. https://doi.org/10.1016/s1078-1439(00)00061-2
Herr. "Timing of cystectomy for superficial bladder tumors." Urologic oncology vol. 5,4 (2000): 162-165. doi: https://doi.org/10.1016/s1078-1439(00)00061-2
Herr HW. Timing of cystectomy for superficial bladder tumors. Urol Oncol. 2000 Jul 01;5(4):162-165. doi: 10.1016/s1078-1439(00)00061-2. PMID: 10869959.
Copy Download .nbib Format: NLM
Commentary. timing of cystectomy for superficial bladder tumors.

Urologic oncology

Lerner SP.
PMID: 10869960
Urol Oncol. 2000 Jul 01;5(4):166-167. doi: 10.1016/s1078-1439(00)00060-0.

No abstract available.

Cite
Lerner SP. Commentary. timing of cystectomy for superficial bladder tumors. Urol Oncol. 2000;5(4):166-167doi: 10.1016/s1078-1439(00)00060-0.
Lerner, S. P. (2000). Commentary. timing of cystectomy for superficial bladder tumors. Urologic oncology, 5(4), 166-167. https://doi.org/10.1016/s1078-1439(00)00060-0
Lerner. "Commentary. timing of cystectomy for superficial bladder tumors." Urologic oncology vol. 5,4 (2000): 166-167. doi: https://doi.org/10.1016/s1078-1439(00)00060-0
Lerner SP. Commentary. timing of cystectomy for superficial bladder tumors. Urol Oncol. 2000 Jul 01;5(4):166-167. doi: 10.1016/s1078-1439(00)00060-0. PMID: 10869960.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 893 entries